Zhe Sang

1.1k total citations · 1 hit paper
12 papers, 618 citations indexed

About

Zhe Sang is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology and Infectious Diseases. According to data from OpenAlex, Zhe Sang has authored 12 papers receiving a total of 618 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Radiology, Nuclear Medicine and Imaging, 6 papers in Molecular Biology and 4 papers in Infectious Diseases. Recurrent topics in Zhe Sang's work include Monoclonal and Polyclonal Antibodies Research (10 papers), Glycosylation and Glycoproteins Research (5 papers) and SARS-CoV-2 and COVID-19 Research (4 papers). Zhe Sang is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (10 papers), Glycosylation and Glycoproteins Research (5 papers) and SARS-CoV-2 and COVID-19 Research (4 papers). Zhe Sang collaborates with scholars based in United States, Israel and China. Zhe Sang's co-authors include Yi Shi, Yufei Xiang, Dina Schneidman‐Duhovny, W. Paul Duprex, Sham Nambulli, Cheng Zhang, Zhengyun Xiao, Heng Liu, Natasha L. Tilston‐Lunel and Douglas S. Reed and has published in prestigious journals such as Science, Cell and Nature Communications.

In The Last Decade

Zhe Sang

12 papers receiving 614 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2

2020 265 citations Yufei Xiang, Sham Nambulli et al. Science profile →

Peers

Countries citing papers authored by Zhe Sang

Since Specialization

Citations

This map shows the geographic impact of Zhe Sang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhe Sang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhe Sang more than expected).

Fields of papers citing papers by Zhe Sang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhe Sang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhe Sang. The network helps show where Zhe Sang may publish in the future.

Co-authorship network of co-authors of Zhe Sang

This figure shows the co-authorship network connecting the top 25 collaborators of Zhe Sang. A scholar is included among the top collaborators of Zhe Sang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhe Sang. Zhe Sang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	Adaptive multi-epitope targeting and avidity-enhanced nanobody platform for ultrapotent, durable antiviral therapy 2024 ·Cell ·Yufei Xiang, Jialu Xu, Briana L McGovern, (unknown), Wei Huang, Zhe Sang, (unknown), (unknown), (unknown), Abraham J. P. Teunissen, Myosotys Rodriguez, (unknown), Derek J. Taylor, Mandy M. T. van Leent, Kris M. White, Adolfo Garcı́a-Sastre, Peijun Zhang, Yi Shi	11
2	Nanobodies: Robust miniprotein binders in biomedicine 2023 ·Advanced Drug Delivery Reviews ·(unknown), Zhe Sang, Yufei Xiang, (unknown), Yi Shi	38
3	Nanobodies as a powerful platform for biomedicine 2022 ·Trends in Molecular Medicine ·(unknown), Zhe Sang, Yi Shi	13
4	Superimmunity by pan-sarbecovirus nanobodies 2022 ·Cell Reports ·Yufei Xiang, Wei Huang, Hejun Liu, Zhe Sang, Sham Nambulli, Jérôme Tubiana, Kevin L. Williams, W. Paul Duprex, Dina Schneidman‐Duhovny, Ian A. Wilson, Derek J. Taylor, Yi Shi	22
5	Structures and photocatalytic activities of bismuth oxyhalides nanoparticles developed by utilizing a simple reaction 2022 ·Materials Science and Engineering B ·Nan Ni, Haibo Li, Lanqi He, (unknown), Zhe Sang, Yingluo Liu, (unknown), Qiushi Wang, Yexiang Tong	2
6	Integrative proteomics identifies thousands of distinct, multi-epitope, and high-affinity nanobodies 2021 ·Cell Systems ·Yufei Xiang, Zhe Sang, (unknown), Jianquan Xu, Yang Liu, Dina Schneidman‐Duhovny, Yi Shi	36
7	Llamanade: An open-source computational pipeline for robust nanobody humanization 2021 ·Structure ·Zhe Sang, Yufei Xiang, İvet Bahar, Yi Shi	34
8	Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes 2021 ·Nature Communications ·Dapeng Sun, Zhe Sang, Yong Joon Kim, Yufei Xiang, Tomer Cohen, (unknown), Alexis Huet, James F. Conway, Ji Sun, Derek J. Taylor, Dina Schneidman‐Duhovny, Cheng Zhang, Wei Huang, Yi Shi	66
9	A resource of high-quality and versatile nanobodies for drug delivery 2021 ·iScience ·(unknown), Yufei Xiang, Sandra Vergara, Apeng Chen, Zhengyun Xiao, Ulises Santiago, (unknown), Zhe Sang, (unknown), Kong Chen, Dina Schneidman‐Duhovny, Carlos J. Camacho, Guillermo Calero, Baoli Hu, Yi Shi	23
10	Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses 2021 ·Science Advances ·Sham Nambulli, Yufei Xiang, Natasha L. Tilston‐Lunel, Linda J. Rennick, Zhe Sang, William B. Klimstra, Douglas S. Reed, Nicholas A. Crossland, Yi Shi, W. Paul Duprex	107
11	<i>Llamanade</i>: An Open-Source Computational Pipeline for Robust Nanobody Humanization 2021 ·SSRN Electronic Journal ·Zhe Sang, Yufei Xiang, İvet Bahar, Yi Shi	1
12	Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2 breakdown → 2020 ·Science ·Yufei Xiang, Sham Nambulli, Zhengyun Xiao, Heng Liu, Zhe Sang, W. Paul Duprex, Dina Schneidman‐Duhovny, Cheng Zhang, Yi Shi	265

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact